CLINICAL MANIFESTATIONS ARISING FROM THE THERAPEUTIC EXTENSION OF TIRZEPATIDE
DOI:
https://doi.org/10.63330/aurumpub.049-003Keywords:
Semiology, Gastrointestinal, Incretins, Weight lossAbstract
Tirzepatide is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, initially indicated for the treatment of type 2 diabetes mellitus. However, its therapeutic extension to the management of obesity and other metabolic conditions has broadened its clinical use. This article critically analyzes, based on pathophysiological mechanisms, the main clinical manifestations associated with the prolonged use of tirzepatide, highlighting gastrointestinal, metabolic, cardiovascular effects and potential rare complications, with emphasis on therapeutic individualization and pharmacovigilance.
Downloads
References
1. ROSENSTOCK, Julio et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, v. 398, n. 10295, p. 143-155, 2021. DOI: 10.1016/S0140-6736(21)01324-6.
2. PATEL, Hiren et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, Obesity and Metabolism, v. 26, n. 2, p. 473-481, 2024. DOI: 10.1111/dom.15333.
3. BARROS, Mike; LEVINE, Joshua A. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS clinical trial program. American Heart Journal, v. 254, p. 241-242, 2022. DOI: 10.1016/j.ahj.2022.10.028.
4. NEVES, João Sérgio et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 trial. Diabetologia, 2025. DOI: 10.1007/s00125-025-06637-7.
5. FRIAS, Juan P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, v. 385, p. 503-515, 2021.
6. DEL PRATO, Stefano et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet, v. 398, n. 10313, p. 1811-1824, 2021.
7. LUDVIK, Bernhard et al. Once-weekly tirzepatide versus insulin degludec as add-on therapy to metformin (SURPASS-3). The Lancet, v. 398, n. 10300, p. 583-598, 2021.
8. DAHL, Dorthe et al. Tirzepatide versus placebo as add-on therapy to insulin glargine (SURPASS-5). JAMA, v. 327, n. 6, p. 534-545, 2022.
9. MIN, Taeeum; BAIN, Stephen C. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Therapy, v. 12, p. 143-157, 2021.
10. SEHGAL, Neil K. R. et al. Self-reported side effects of semaglutide and tirzepatide in online communities. arXiv preprint, 2026.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
